• Roundtable
    April 16, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Thursday, May 07, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Roundtable
    March 31, 2026

    Following our GBS Operating Model FutureCast workshop, Everest Group is convening a select group of GBS leaders for an interactive working session on Tuesday, April 14, to pressure test emerging perspectives on reimagining the operating model in the age of agentic AI.  …
  • Viewpoint
    March 25, 2026

    Life sciences enterprises are operating in a market access environment defined by pricing reforms, heightened transparency, and evolving health technology assessment expectations. Market access now begins well before regulatory approvals, requiring early evidence alignment, global-local coordination,…
  • Viewpoint
    March 13, 2026

    Life sciences commercial models are fundamentally shifting as Healthcare Professional (HCP) engagement becomes more hybrid, data-driven, and personalization-led. Legacy approaches built around static segmentation, fixed call plans, and siloed functional execution struggle to keep pace with…
  • Provider Compendium
    Nov. 06, 2025

    Clinical Data Management (CDM) operations have become a strategic priority for life sciences enterprises as they face growing trial complexities, expanding data volumes, and the integration of decentralized and real-world data sources. These dynamics are reshaping…
  • Market Insights™
    Nov. 05, 2025

  • In 2006, I visited my first captive center in Bengaluru. At the time, the model was still in its formative years – many multinational organizations were only beginning to explore the potential of setting up their own in-house centers…
  • Blog
    Nov. 02, 2025

    The clinical outsourcing market is undergoing a transition with the emergence of specialist-focused Clinical Research Organizations (CROs). A specialist CRO concentrates its expertise in a defined area, such as a therapeutic focus, trial phase or technology, or geographic niche, rather than offering broad,…
  • State of the Market
    Oct. 01, 2025

    The surge in case volumes, more stringent regulatory demands, and therapeutic areas’ rising complexities are significantly transforming pharmacovigilance (PV). As the industry adapts to more tailored reporting requirements and longer patient monitoring periods, enterprises are under…
  • Provider Compendium
    Sep. 16, 2025

    Pharmacovigilance (PV) operations have become a strategic priority for life sciences enterprises facing heightened regulatory scrutiny, evolving safety standards, and growing complexity across global markets. This report provides an in-depth assessment of 12 leading PV service…
  • PEAK Matrix®
    Aug. 19, 2025

    Clinical Data Management (CDM) is rapidly transforming as life sciences enterprises navigate increasing trial complexity, heightened regulatory scrutiny, and the expansion of decentralized and real-world data sources. CDM now plays a strategic role in enabling faster,…
  • LinkedIn Live
    July 24, 2025

    Watch on LinkedIn Global Capability Centers (GCCs) in India rapidly evolved from cost-efficient service hubs to strategic centers of innovation, product development, and digital transformation for global enterprises. As this evolution accelerated, talent development became a…
  • Viewpoint
    June 12, 2025

    Life sciences enterprises are increasingly turning to Real-world Evidence (RWE) as an essential input for decision-making across the product life cycle – from early-stage R&D to post-market access and safety. RWE offers validated insights into treatment…
  • Viewpoint
    June 03, 2025

    As life sciences enterprises navigate the clinical development’s growing complexity due to advanced therapies, increased data volumes, and the need for operational agility, outsourcing models are evolving in response. Sponsors now seek flexible, cost-efficient, and expertise-driven…
  • Blog
    May 23, 2025

    On May 12, 2025, President Donald Trump signed a high-impact executive order titled “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.” The order directed the U.S. Department of Health and Human Services (HHS) to implement a…
  • Briefings
    May 14, 2025

    Everest Group hosted its exclusive launch event for its new Advanced SciTech Service. This program is designed to help you navigate the complex landscape of emerging science and technology, enabling you to integrate cutting-edge innovations effectively…
  • Viewpoint
    May 07, 2025

    Increasing trial complexity, growing data volumes, and the rise of decentralized and real-world data sources are fundamentally transforming the clinical trial landscape. Traditional Clinical Data Management (CDM) processes are largely manual and rely on siloed data…
  • PEAK Matrix®
    April 03, 2025

    Pharmacovigilance (PV) has evolved into a strategic imperative, driven by intensified regulatory scrutiny and an increasing focus on patient safety. Pharmaceutical companies now face a rapidly evolving landscape characterized by rising adverse event volumes, fragmented real-world…
  • Blog
    April 01, 2025

    Clinical trials are becoming more complex, diverse, and data-intensive than ever before. With decentralized trials, real-world evidence, and multi-source data streams reshaping the research landscape, effectively managing clinical data is no longer just an operational necessity,…
  • LinkedIn Live
    Feb. 13, 2025

    Watch On LinkedIn Step into the future in this insightful LinkedIn Live with Everest Group experts Hrishi Raj Agarwalla, Vice President, and Ashish Sehdev, Vice President. Join this virtual session as they decode the market shifts…

Items per page